Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Oyster Point Pharma, Inc. (OYST)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | |
| Cost of goods sold | 23.1% | 9.9% | 6.8% | 6.2% | 0.0% | | | |
| Gross profit | 76.9% | 90.1% | 93.2% | 93.8% | 100.0% | | | |
| Sales and marketing | 672.9% | 400.4% | 389.0% | 340.6% | 216.4% | | | |
| Research and development | 95.6% | 65.8% | 84.7% | 98.8% | 169.9% | | | |
| General and administrative | 117.5% | 66.4% | 59.7% | 48.4% | 159.4% | | | |
| Depreciation | 1.6% | 0.9% | 0.7% | 0.6% | 0.6% | | | |
| EBIT | -809.1% | -442.5% | -440.3% | -393.9% | -445.6% | | | |
| Pre-tax income | -902.0% | -493.4% | -475.9% | -410.2% | -450.5% | | | |
| Income taxes | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | |
| Net income | -902.0% | -493.4% | -475.9% | -410.2% | -450.5% | | | |
|